NCT02999646

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC

Completed NA Last updated 28 September 2023

What this trial tests

NA trial testing MVX-ONCO-1 in Head and Neck Squamous Cell Carcinoma in 16 participants. Completed in 29 June 2023.

Timeline

25 July 2018

Primary endpoint
25 January 2023

29 June 2023

Quick facts

Lead sponsor	Maxivax SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	25 July 2018
Primary completion	25 January 2023
Estimated completion	29 June 2023
Sites	4 locations across Switzerland

Drugs / interventions tested

• MVX-ONCO-1

Conditions studied

• Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

Maxivax SA

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 consists of dead tumor cells from the patient itself and genetically modified cells within a capsule. The whole treatment takes 9 weeks. At weeks 1, 2, 3, 4, 6 and 8, the tumor cells are injected underneath the skin and two capsules are implanted for a week. At weeks 2, 3, 4, 5, 7 and 9 the capsules are removed again. The patients are then followed-up for 5 years.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.
   Horton JD, Knochelmann HM, Day TA, Paulos CM, et al · · 2019 · cited 65× · PMID 30961829 · DOI 10.1016/j.trecan.2019.02.007
2. Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response.
   Pérez-Baños A, Gleisner MA, Flores I, Pereda C, et al · · 2023 · cited 54× · PMID 37355722 · DOI 10.1038/s41416-023-02327-6
3. Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.
   Tan YS, Sansanaphongpricha K, Prince MEP, Sun D, et al · · 2018 · cited 39× · PMID 29533731 · DOI 10.1177/0022034518764416
4. Targeting Head and Neck Cancer by Vaccination.
   Wang C, Dickie J, Sutavani RV, Pointer C, et al · · 2018 · cited 38× · PMID 29740440 · DOI 10.3389/fimmu.2018.00830
5. Personalized cancer vaccination in head and neck cancer.
   Shibata H, Zhou L, Xu N, Egloff AM, et al · · 2021 · cited 37× · PMID 33368875 · DOI 10.1111/cas.14784
6. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
   Wang H, Zhao Q, Zhang Y, Zhang Q, et al · · 2021 · cited 33× · PMID 34305889 · DOI 10.3389/fimmu.2021.652054
7. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma.
   Yu C, Li Q, Zhang Y, Wen ZF, et al · · 2022 · cited 31× · PMID 36092724 · DOI 10.3389/fcell.2022.941750
8. Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers.
   Zhou JZ, Jou J, Cohen E. · · 2021 · cited 29× · PMID 35008197 · DOI 10.3390/cancers14010033